FDA
-
-
-
-
-
-
-
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
-
-
-
-
-
-
-
AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
-
-
-
-
-
-
-
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting
-
-
-
-
-
-
-
Kura Oncology (KURA) and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting
-
-
-
-
-
-
-
First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome
-
-
-
-
-
-
-
Ardelyx (ARDX) Announces Tenapanor for Hyperphosphatemia Approved in Japan
-
-
-
-
-
-
-
Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin’s Lymphoma in Japan
-
322,898 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

